Pancreatic Metastases Originating from Intestinal Neuroendocrine Tumours Abstract #2733

Introduction: Pancreatic metastases are rare, accounting for 1 to 2% of pancreatic tumours. Data on pancreatic metastases of intestinal NETs are lacking.
Aim(s): Description of frequency and outcome of patients with pancreatic metastases of intestinal neuroendocrine tumours (NET).
Materials and methods: In 1998 we established a database for patients with NET at our hospital. We searched this clinical database for all patients with intestinal NET and pancreatic metastases (PM).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Anja Rinke

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2786 Outcome of NET Liver Metastases Treated by TAE Using Microspheres
Introduction: Liver metastases are common in patients with neuroendocrine tumors (NETs), which are associated with the prognosis. Transarterial embolization (TAE) is one of the options for selective therapy in patients with multiple unresectable progressive liver metastases after chemotherapy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Xiaoliang Chen
Authors: Chen X, Hu L
#2798 Risk of Pre-Operative Understaging of Duodenal Neuroendocrine Tumors at Conventional Imaging: When Surgery Becomes the First Choice
Introduction: Duodenal neuroendocrine neoplasms (dNENs) are heterogeneous tumors that can exhibit aggressive behavior, with loco-regional nodes and distant metastases. Pre-treatment staging is the basis for planning either surgical or endoscopic treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: dr Sara Massironi
#2843 Metastatic Risk in Pancreatic Neuroendocrine Tumors: A 16-Year Experience from Bogotá, Colombia. A Series Cases
Introduction: Pancreatic neuroendocrine tumors (pNET) are rare, have a wide range of phenotypes, increase incidence in recent years; which represents a challenge in diagnosis, treatment, and follow-up
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Deyanira González Devia
#2846 Whole Genome DNA Methylation Profiling Identifies Neuroendocrine Tumor Origin
Introduction: Determining the origin of a neuroendocrine tumor (NET) of unknown primary can be challenging. Liver metastases can originate from any organ in the body, while pulmonary NETs can be metastases but also primary tumors. This especially holds true for Multiple Endocrine Neoplasia Type 1 patients, who often have multiple primary pancreatic and intestinal NETs. It is important to know the origin of the primary tumor since resection or ablation is crucial in case of treatment with curative intent. Furthermore, the site of origin determines prognosis, treatment options and eligibility for clinical trials.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Wenzel M Hackeng
#2848 Correlation between Clinicopathological Features and Distant Metastases in Pancreatic Neuroendocrine Neoplasm: A National Multicenter 10-Year Retrospective Study
Introduction: The incidence of pancreatic neuroendocrine neoplasm (PNEN) is increasing, and the prognosis of patients with PNEN is quite different.So, it is of great significance to study the effect of different pathological features on the prognosis of patients with PNEN.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Xinyi Zhu
Authors: Zhu X, Yang H, Lu H, Shi S, ...